Key statistics
On Tuesday, Novocure Ltd (N2VC34:SAO) closed at 9.50, -28.84% below its 52-week high of 13.35, set on Jul 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.50 |
---|---|
High | 9.50 |
Low | 9.50 |
Bid | 5.01 |
Offer | 15.00 |
Previous close | 9.50 |
Average volume | 1.00 |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Nov 12 2024 20:54 GMT.
More ▼
Press releases
- Novocure Appoints Christoph Brackmann as Chief Financial Officer
- Novocure Reports Third Quarter 2024 Financial Results
- Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors
- FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
- Novocure to Report Third Quarter 2024 Financial Results
- Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
- Novocure Announces Planned CEO Transition
- Novocure to Participate in 2024 Wells Fargo Healthcare Conference
More ▼